Table 1.

Vaccination studies in non-small cell lung cancer

	Immunotherapy	Study	Outcome
Protein or peptide based vaccines	MAGE-A3	Vansteenkiste et al. [22]. Phase II; 182 patients with resected stage IB-II.	Immune response. Clinical response. Trend toward survival benefit.
	EGF	Gonzalez et al. [24]. 83 patients with stage IIIB/IV.	Immune response. Clinical response. Survival benefit for vaccinated patients (8 months) vs. nonrandomized controls (4.5 months).
	MUC-1	Butts et al. [35, 36]. Phase IIB; 171 patients with stage IIIB/IV.	Immune response. Clinical response. Trend toward survival benefit.
	IDM-2101 (multiple antigens)	Barve et al. [37]. Phase II; 63 patients with stage IV.	Immune response. Clinical response. Trend toward survival benefit.
Tumor cell vaccines expressing	GM-CSF	Nemunaitis et al. [40]. Phase I/II; 43 patients with stage IB-IV. Nemunaitis et al. (GVAX) [41]. Phase I/II; 49 patients with stage IIIA/IV.	Immune response. Clinical response. 3/33 advanced-stage patients (2 BACs) durable CRs lasting 6, 18, and ≥ 22 months. OS correlated with level of GM-CSF secretion by vaccine. Immune response. No clinical response.
	TGF-β antisense	Nemunaitis et al. [51]. Phase II; 75 patients with stage II-IV.	Immune response. Clinical response.